Cavanagh Bethany J 4

What Happened
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM), sold 6,198 shares of BEAM common stock in open-market transactions on January 22, 2026. The reported proceeds were $216,933. The weighted average price reported was $35.00, with individual sale prices in the range $35.00 to $35.015. This was a sale (not a purchase) and is often considered routine insider selling.

Key Details

• Transaction date: 2026-01-22 (reported on Form 4 filed 2026-01-26). Filing appears timely under the two-business-day Form 4 rule.
• Shares sold: 6,198; weighted average price: $35.00; reported total value: $216,933.
• Price range: $35.00 to $35.015 (the reporting person can provide per-price breakdown on request).
• Footnote: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted September 19, 2025 (pre-arranged trading plan).
• Shares owned after transaction: not specified in the summary data provided.

Context
Sales under a Rule 10b5-1 plan are pre-arranged and commonly used to execute transactions without regard to short-term insider knowledge; they are informative about executed volume but do not necessarily indicate the insider’s current view of the company. This report documents a routine disposition rather than an acquisition or option exercise.